Total Valuation
Vaxcyte has a market cap or net worth of €7.42B. The enterprise value is €7.17B.
Market Cap€7.42B
Enterprise Value€7.17B
Share Statistics
Vaxcyte has 144,397,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding144,397,670
Owned by Insiders0.76%
Owned by Institutions0.08%
Financial Efficiency
Vaxcyte’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -32.45%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-32.45%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee0.00
Profits Per Employee-1.51M
Employee Count507
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vaxcyte is ―. Vaxcyte’s PEG ratio is -0.17.
PE Ratio―
PS Ratio0.00
PB Ratio2.34
Price to Fair Value2.34
Price to FCF-9.38
Price to Operating Cash Flow-10.64
PEG Ratio-0.17
Income Statement
In the last 12 months, Vaxcyte had revenue of 0.00 and earned -766.63M in profits. Earnings per share was -5.63.
Revenue0.00
Gross Profit0.00
Operating Income-923.67M
Pretax Income-766.63M
Net Income-766.63M
EBITDA-741.77M
Earnings Per Share (EPS)-5.63
Cash Flow
In the last 12 months, operating cash flow was -769.93M and capital expenditures -1.76M, giving a free cash flow of -771.68M billion.
Operating Cash Flow-769.93M
Free Cash Flow-771.68M
Free Cash Flow per Share-5.34
Dividends & Yields
Vaxcyte pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change87.04%
50-Day Moving Average43.74
200-Day Moving Average41.66
Relative Strength Index (RSI)61.61
Average Volume (3m)39.00
Important Dates
Vaxcyte upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Vaxcyte as a current ratio of 7.91, with Debt / Equity ratio of 3.88%
Current Ratio7.91
Quick Ratio7.91
Debt to Market Cap0.02
Net Debt to EBITDA-0.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vaxcyte has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vaxcyte EV to EBITDA ratio is -8.54, with an EV/FCF ratio of -9.46.
EV to Sales0.00
EV to EBITDA-8.54
EV to Free Cash Flow-9.46
EV to Operating Cash Flow-9.66
Balance Sheet
Vaxcyte has €1.74B in cash and marketable securities with €116.30M in debt, giving a net cash position of €1.62B billion.
Cash & Marketable Securities€1.74B
Total Debt€116.30M
Net Cash€1.62B
Net Cash Per Share€11.23
Tangible Book Value Per Share€19.73
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vaxcyte is €101.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€101.70
Price Target Upside103.41% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-58.14%